R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Oncology Account Manager

Field SalesConfirmed live in the last 24 hours
Full-timeRemote in USA$150k - $230k

About the Job

Requirements

  • A master's or bachelor's degree and 12–15+ years of biopharma industry experience are required.
  • At least 8–12+ years of prior experience in oncology product sales is required.
  • A proven track record of product launch success in the oncology therapeutic space is required.
  • Oral oncolytic product launch experience is required.
  • Experience launching oncology products with companion diagnostics is required.
  • A proven performance record in highly competitive marketplaces is required.
  • A proven performance record in solo-representative selling environments is required.
  • Demonstrated success operating in small- or midsize biotechnology environments is required.
  • Ability to meet territorial travel requirements is required.
  • Ability to travel to meetings, training, and programs as necessary is required.
  • Effectiveness in highly collaborative and cross-functional working environments is required.
  • A valid driver's license is required.
  • Permanent residence in the assigned territory is required.
  • Approximately 50% travel is required.

Responsibilities

  • Effectively market the company’s product portfolio in the designated territory.
  • Exceed assigned territory performance goals by positioning the benefits and use of products for appropriate patients.
  • Manage time effectively by directing efforts toward engagements that drive brand value and prioritizing activities that positively impact patients.
  • Partner with internal stakeholders to remove barriers to care and help ensure eligible patients receive timely access to products.
  • Flex between virtual and in-person engagements and develop business plans that consider account communication preferences.
  • Analyze market data and turn insights into business plans, implementing those plans by engaging key targets through call optimization and resource utilization.
  • Develop sustained customer relationships across assigned accounts and challenge customers through value-driven solutions.
  • Represent company brands professionally, compliantly, ethically, and effectively.
  • Maintain a thorough understanding of disease states, company products, and competitor offerings, and articulate product value across digital and live communication channels.
  • Understand reimbursement processes and fulfillment pathways for oral oncolytics.
  • Manage the territory effectively and apply selling competencies.
  • Creatively gain access to customers in the modern landscape.
  • Drive team effectiveness and shared goals by sharing expertise and information.
  • Manage territory resources and budget effectively.
  • Comply with laws, regulations, and policies governing employee conduct.
  • Embody company core values and cultivate an energized team culture focused on patient impact.

Desired Qualifications

  • Experience in the non-small cell lung cancer (NSCLC) oncology space is preferred.
  • An advanced degree such as an MBA, Doctor of Pharmacy (PharmD), or PhD is preferred.
  • Strong organization, planning, project management, technical, and analytical skills are preferred.
  • Other relevant experience, such as sales operations, market research, or market access, is preferred.
  • Ability to work independently to execute strategic and tactical plans under tight timelines is preferred.
  • Ability to deliver compelling presentations to individuals and groups and adapt messaging to maximize audience engagement is preferred.
  • High proficiency in Microsoft PowerPoint, Excel, and Word is preferred.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs